April 1st 2025
The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss.
Eye Care Symposia in Los Angeles
April 25-26, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
19th Annual Controversies in Modern Eye Care
May 4, 2025
Register Now!
(CME Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(COPE Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Collaborative Care Symposium
May 30-31, 2025
Register Now!
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (CME Track)
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (COPE Track)
View More
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Practical Approaches to Modern Dry Eye Treatment and Management
June 25, 2025
Register Now!
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (CME Credit)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (COPE Credit)
View More
CO2 Laser a useful tool for nonpenetrating deep sclerectomy
August 1st 2004Fort Lauderdale, FL-Initial clinical trial experience suggests that CO2 laser-assisted nonpenetrating deep scle- rectomy (NPDS) holds promise as an excellent option for glaucoma therapy, said Ehud I. Assia, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Read More
Relative toxicity of four ophthalmic antibiotics studied
August 1st 2004Fort Lauderdale, FL-In a comparison study that has implications for wound healing in surface ablation procedures, investigators found that four commonly used topical ophthalmic antibiotics-moxifloxacin (Vigamox, Alcon), levofloxacin (Quixin, Santen), gatifloxacin (Zymar, Allergan), and ofloxacin (Ocuflox, Allergan)-all showed evidence of toxicity on human corneal epithelial cells, with moxifloxacin causing the least amount of toxicity.
Read More
Outcomes favorable in 2-year experience with silicone IOL
July 15th 2004San Diego - Two-year follow-up of eyes with the ClariFlex with OptiEdge silicone IOL (AMO) implanted show that the second-generation silicone IOL with its novel edge design is performing well. Furthermore, risk of posterior capsular opacification (PCO) and glare was minimal, according to the results of a study presented by Elizabeth A. Davis, MD, FACS, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Read More
Secrets of the glaucoma surgeon: preventing complications
June 5th 2004The use of antiproliferative agents has helped increase thelikelihood of successful filtering surgery by inhibiting the wound healingresponse. The problem is that these agents also contribute to the risk ofbleb leak and bleb-associated infection, reported Paul J. Lama, MD, of theUniversity of Medicine and Dentistry of New Jersey, Newark, and the Veterans'Administration Medical Center, East Orange, NJ.
Read More
Peripheral iris fixation technique yields promising results
June 1st 2004Baltimore-Peripheral iris fixation of a foldable posterior chamber IOL using a modified McCannel suture appears to be a useful technique for the management of delayed-onset within-the-bag IOL subluxation in eyes with pseudoexfoliation syndrome, said Aruoriwo M. Oboh-Weilke, MD
Read More
Study: modulator in wound healing with trabeculectomy
May 1st 2004Dorado, Puerto Rico-After positive results from a European clinical trial showed transforming growth factor-b2 (TGF-b2) mono clonal antibody was effective in delaying wound healing after first-time trabeculectomy, U.S. investigators are undertaking a multicenter clinical trial to compare the new agent with 5-fluorouracil (5-FU), reported Marshall N. Cyrlin, MD.
Read More
Lens aims to increase range of accommodation
May 1st 2004San Francisco-Clinical trials are under way in centers in Germany and Colombia to evaluate a dual-optic accommodating IOL (Synchrony, Visiogen) designed to offer amplified, consistent accommodation across a wide range of IOL powers, said Stephen D. McLeod, MD.
Read More
Refractive Lens Exchange holds promise as option to LASIK
May 1st 2004Dorado, Puerto Rico - Refractive lens exchange (RLE) does look promising as a viable option to corneal refractive procedures, particularly in those patients with high myopia or hyperopia. However, surgeons need to review the advantages and limitations of the intraocular procedure carefully with patients, according to Terrence P. O'Brien, MD.
Read More
Bleb leaks becoming more common with antimetabolite use
April 15th 2004Madison, WI-Leaking blebs occur fairly often now that antimetabolites are used in glaucoma surgery. A variety of treatment approaches can be used to manage them, and the outcomes are usually successful if care is taken in the management process, according to Todd Perkins, MD.
Read More
ICLs gain acceptance with proven tolerability
April 15th 2004Mendoza, Argentina-Intraocular contact lenses (ICLs) (STAAR Surgical) have been used for many years outside the United States, and the results indicate that the ICLs can be tolerated over the long term. More patients have been opting to have this type of lens implanted following a previous LASIK procedure, and their visual outcomes have been good, according to Roberto Zaldivar, MD.
Read More
Phakic IOL addresses high levels of refractive errors
April 15th 2004Carlsbad, CA-The Vision Membrane multifocal IOL (Vision Membrane Technologies Inc.) is a silicone anterior chamber phakic IOL that is intended to treat patients with myopia, hyperopia, and presbyopia. The IOL is extremely thin, even for cases of extreme myopia, and can eliminate the glare and halos normally associated with corneal refractive procedures.
Read More